Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

Related Articles by Review for PubMed (Select 20048335)

1.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

2.

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

Kolb EA, Pan Q, Ladanyi M, Steinherz PG.

Cancer. 2003 Dec 15;98(12):2643-50. Review.

3.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
4.

Spotlight on imatinib mesylate in chronic myeloid leukemia.

Curran MP, Croom KF, Goa KL.

BioDrugs. 2004;18(3):207-10. Review.

PMID:
15161340
5.
6.
7.

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H.

Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S51-7. Review.

PMID:
17382013
8.

Immunotherapy in chronic myelogenous leukemia.

Guilhot F, Roy L, Martineua G, Guilhot J, Millot F.

Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S64-70. Review.

PMID:
17382015
9.

Immunology and immunotherapy of chronic myeloid leukemia.

Ilander M, Hekim C, Mustjoki S.

Curr Hematol Malig Rep. 2014 Mar;9(1):17-23. doi: 10.1007/s11899-013-0190-1. Review.

PMID:
24390549
10.

How I monitor residual disease in chronic myeloid leukemia.

Radich JP.

Blood. 2009 Oct 15;114(16):3376-81. doi: 10.1182/blood-2009-02-163485. Epub 2009 Aug 6. Review. Erratum in: Blood. 2014 Jan 9;123(2):301.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk